Promising breast cancer combo trial halted early – only 6 patients enrolled
NCT ID NCT06408168
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tested repotrectinib with or without fulvestrant in people with a rare, hormone-positive, HER2-negative metastatic breast cancer called invasive lobular carcinoma. The goal was to see if the combination could control the disease after standard treatments had stopped working. However, the study was terminated early and only enrolled 6 participants, so we have very little information about how well it worked or its safety.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- repotrectinib and fulvestrant
- What this could lead to
- If it worked, this could point toward a new treatment option for a rare type of breast cancer that has stopped responding to standard therapy.
- What could go wrong
- The trial was terminated early with only 6 participants, so results are very limited. It is unclear if the combination is safe or effective, and no conclusions can be drawn.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HORMONE RECEPTOR-POSITIVE HUMAN EPIDERMAL GROWTH FACTOR 2-NEGATIVE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.